Oxidative Monitoring in ICU Patients.

NCT ID: NCT02114853

Last Updated: 2014-04-15

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 150 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-04-30
• Study Completion Date: 2016-04-30

Brief Summary

Sepsis is common in the ICU and is associated with high mortality that reaches up to 60%, increased duration of hospitalization and additional costs [1,2].Early diagnosis and stratification of severity are of great importance in order to timely apply proper and adequate treatment [3].

Oxidative stress is implicated in inflammation and sepsis and sepsis severity seems to correlate with increased oxidative stress [7,8]. Monitoring of oxidative stress has been done so far with various markers which reflect the different pathways of oxidative stress as is oxidosis of lipids, proteins, nucleic acids; yet the antioxidant capacity of various enzymes and vitamins has been studied [9]. However these methods do not reflect oxidative stress as a whole, are time consuming, need special laboratory procedures and are costly.

Oxidation-reduction potential is a new technique that enables bedside assessment of the oxidative status. It is based on measuring the balance of oxidants and reductants in human blood with a simple plasma test that reports results immediately.

Hypothesis

Oxidation-reduction potential, used for oxidative monitoring in ICU patients, might correlate with sepsis severity and may be used in addition to other clinical and/or inflammatory markers to assess severity and possibly prognosis.

Detailed Description

4. Procedures/evaluation of the trial 4.1 Evaluation at entry

The selected oxidative parameters that will be assessed in this study will be:

oxidation-reduction potential (ORP) in plasma thiobarbituric acid-reactive substances (TBARS) in plasma protein carbonyls (CO) in plasma total antioxidant capacity in plasma (TAC)

The inflammatory parameters that will be measured are:

C-Reactive protein in plasma Brain Natriuretic Peptide (BNP) in whole blood Troponin-I in whole blood Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood

.2. Time of assessment Measurements will be performed within the first 24hours upon entry and daily regarding the ORP detection and oxidative markers for a period of 10 days, if sepsis is not present.

In the presence of sepsis diagnosis, measurements will be performed daily until the 7th day of the septic episode plus at the time of sepsis resolution or at the point of death and at the end of the follow-up period, on the 28th day.

For the inflammatory markers measurements will be performed as followed:

C-Reactive protein in plasma daily Brain Natriuretic Peptide (BNP) in whole blood at admission and/or sepsis diagnosis and every 72h until resolution/death and on the 28th day.

Troponin-I in whole blood at admission and/or sepsis diagnosis and during sepsis according to heart ultrasound findings and on the 28th day.

Soluble CD14 subtype presepsin ( sCD14-ST) in whole blood

4.3. Blood collection and store Arterial blood from an indwelling arterial catheter will be drawn from each patient.

The blood will be kept in a tube with sodium heparin, immediately centrifuged at 1,370g and a small portion will be used for the detection of ORP while the remaining fraction will be collected and stored at -80o C until further analysis.

4.4. Assessment of the oxidative markers ORP will be immediately assessed using the device RedoxSYS of Luoxis (Ampio Pharmaceuticals Inc, CO, USA) The device reports two measurements static ORP, and capacity for every plasma sample [11 ].

For TBARS, a slightly modified assay of Keles et al. [12 ] will be used, while plasma protein carbonyls will be determined based on the method of Patsoukis et al. [13 ]. TAC determination will be based on a previously described method [14].

5. Data collection

Data to be recorded for each subject are:

Past medical history Patients wil be divided in medical, surgical and trauma groups. (comprising patients with renal disease, diabetes, Chronic obstructive pulmonary disease, coronary artery disease, immunocompromized states, cerebrovascular disease).

Data to be recorded during ICU stay for each subject, are:

APACHE II score at entry SOFA score at enry and upon all other timepoints. Sepsis severity (sepsis, severe sepsis, septic shock), upon diagnosis and for the rest timepoints.

In all timepoints:

Oxygen concentration (FiO2), partial oxygen pressure , mode of mechanical ventilation, static compliance, tidal volume.

Blood pH Blood lactate Levels of vasopressors and inotropes (noradrenaline, adrenaline, dopamine, dobutamine, vasopressin. The peak dose will be recorded within the last 24h).

Temperature (peak value in the last 24h)

Every day a full blood count and biochemical examinations will take place. Data to be recorded in all timepoints are:

Blood leukocyte count Platelets Fibrinogen Prothrombin time/Partial thromboplastin time Urea/Creatinine Transaminases Bilirubin (total, conjugated) Uric acid Blood albumin (every 3 days).

In addition :

Surveillance cultures upon entry. Blood, bronchial secretions, urine cultures at sepsis diagnosis and of any other fluid or tissue connected with the sepsis cause according to the attending physician. Specimens of all cultures will be repeated during the septic episode according to the attending physician's opinion and will also be recorded.

Conditions

Sepsis

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• All subjects entering to the ICU and are expected to stay for more than 72 hours are eligible to participate.

Sepsis is recognized, defined and categorized according to the Surviving Sepsis Campaign criteria [10].

Exclusion Criteria

i) patients who receive chronic renal replacement therapy, iii) age under 18, iv) patients with body mass index<18, v) antioxidant supplementation two weeks prior to ICU admission

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Thessaly

OTHER

Sponsor Role: lead

Responsible Party

Maria Karapetsa

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Epaminondas Zakynthinos, Prof.

Role: PRINCIPAL_INVESTIGATOR

University of Thessaly

Maria Karapetsa, MD

Role: PRINCIPAL_INVESTIGATOR

University of Thessaly-University Hospital of Larissa,ICU

Locations

ICU, University Hospital of Larissa

Larissa, Thessaly, Greece

Site Status: RECRUITING

Countries

Greece

Facility Contacts

Maria Karapetsa, MD

Role: primary

mkarapetsa@gmail.com

+302413501280

Epaminondas Zakynthinos, Professor of Intensive Care

Role: backup

ezakynth@med.uth.gr

+302413501566

Other Identifiers

4784.02

Identifier Type: -

Identifier Source: org_study_id